Atossa Therapeutics
ATOS· Manufacturing· Fiscal year ends in December
No proxy on file names the CEO of Atossa Therapeutics.
Executives2
See all- 1Steven C. Quay, M.D., Ph. D.FY2024
- 2Heather Rees, CPA (inactive)FY2024
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allAtossa Therapeutics paid its 2 named executives $3.9M in total in FY2024 (Dec).
| Name | |||
|---|---|---|---|
| Steven C. Quay, M.D., Ph. D. | |||
| Heather Rees, CPA (inactive) | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Atossa Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Activity
Filings6
See all| Annual report | 10-K | Mar 25, 2026 | FY2025 |
| Proxy statement | DEF 14A | Dec 22, 2025 | — |
| Proxy statement | DEF 14A | Mar 26, 2025 | FY2024 |
| Annual report | 10-K | Mar 25, 2025 | FY2024 |
| Proxy statement | DEF 14A | May 23, 2024 | FY2023 |
| Annual report | 10-K | Apr 1, 2024 | FY2023 |
